medRxivGenetic & Genomic MedicinePreprint
Long-read sequencing enables high-accuracy mitochondrial heteroplasmy detection in Parkinson's disease
Theresa LüthiD, Susen SchaakeiD, Christoph Much, Mary Megan Belyea, Philip SeibleriD, Anne GrünewaldiD, Patrick MayiD, Christine KleiniD, Hansi WeißensteineriD, Joanne TrinhiD
Abstract
BackgroundLow-frequency heteroplasmic mitochondrial DNA (mtDNA) variants are associated with aging and neurological diseases, including Parkinsons disease (PD). Targeted deep mtDNA sequencing using PacBio HiFi long reads has the potential to resolve heteroplasmy across the full mitochondrial genome with high accuracy. MethodsTo validate Vega PacBio sequencing for detecting mtDNA heteroplasmy, we analyzed four predefined mixtures of two mtDNA haplotypes. We generated a single long-range PCR amplicon covering the entire mitochondrial genome. These amplicons were mixed at predefined ratios (minor mixture haplotype component: 5%, 2%, 1%, and 0.1%). Variant calling was performed using Mutserve2, and accuracy was assessed by calculating the F1 score from comparisons between expected and detected variants. Full-length mtDNA PacBio sequencing was applied to investigate heteroplasmy across fibroblast passages derived from five LRRK2 p.Gly2019Ser variant carriers (n=3 affected with PD and n=2 unaffected carriers). Changes in mtDNA heteroplasmy level and variant load were assessed longitudinally using a linear mixed model. ResultsThe single-amplicon approach enabled full-length haplotype resolution without amplification bias associated with overlapping PCR strategies. The F1 score of the predefined mixtures was 1.0 for heteroplasmy levels between 5% and 1% and remained high (0.91) at 0.1%. We detected n=10/62 variants discordant with the Illumina reference at the 0.1% mixture, but sensitivity remained very high at 1.00 in that mixture. Detected minor variants closely matched expected heteroplasmy levels, with average variant levels of 0.057 (5%), 0.022 (2%), 0.011 (1%), and 0.001 (0.1%). Across twelve fibroblast passages, we observed fewer mtDNA heteroplasmic variants ({beta}=-3.2, p=0.026). Increased heteroplasmic variant load over time was also associated with older age ({beta}=1.50, p=0.001) and PD affection status ({beta}=5.0, p=1.0 x 10-) in LRRK2 variant carriers. Notably, we observed distinct patterns of heteroplasmic variants that either increased or decreased in heteroplasmy level across passages. ConclusionPacBio HiFi sequencing, combined with a single-amplicon strategy, enables accurate full-length mtDNA heteroplasmy detection and longitudinal analysis, providing a valuable tool for studying mitochondrial variation and dynamics in disease.
- organism: human
- assay: whole-genome sequencing
- research focus: variant calling
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Novel mitochondrial variants associated with Parkinson's disease reveal a high heteroplasmy-weighted polygenic risk score in Brazilians
Gustavo Barra Matos, Matheus Caetano Epifane-de-Assunção, … Bruno Lopes Santos‐Lobato·medRxiv·Jan 16, 2026
- Mitochondrial DNA heteroplasmy distinguishes disease manifestation in PINK1- and PRKN-linked Parkinson's disease
Joanne Trinh, Andrew A. Hicks, … Anne Grünewald·BrainPeer-reviewed·Dec 7, 2022
- Chasing a moving target: Detection of mitochondrial heteroplasmy for clinical diagnostics
Eric J. White, Tristen Ross, … John F. Thompson·bioRxiv·Nov 19, 2017
- Analysis of heterozygous PRKN variants and copy number variations in Parkinson's disease
Eric Yu, Uladzislau Rudakou, … Ziv Gan‐Or·Movement DisordersPeer-reviewed·Sep 24, 2020
- MOLECULAR ANALYSIS OF MITOCHONDRIAL COMPLEX I IN THE RESPONSIVENESS TO LEVODOPA IN PARKINSON'S DISEASE
Ana Gabrielle Bispo, Felipe Gouvêa de Souza, … Giovanna C. Cavalcante·medRxiv·Nov 10, 2025
- Multi-ancestry analysis of POLG variants in Parkinson's disease
Yi Wen Tay, Inas Elsayed, … María Teresa Periñán·medRxiv·Jun 8, 2026